Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14499184 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL3774089 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL2631528 | 0.82 | SMN1; SMN2 (0.66) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL29763579 | 0.82 | SMN1; SMN2 (0.66) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL13440741 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL11200266 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL7532390 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL6361845 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL14833607 | 0.78 | POLB (0.64) | SMN1; SMN2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL25825666 | 0.78 | GAA (0.51) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4076423-A1 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087440-A | TRPML modulators | 卡斯玛治疗公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2018-07-26 | — | — | US | disclosed |
| EP-2911671-B1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-9925187-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| EP-1848430-A2 | NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | Reddy US Therapeutics, Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20060178514-A1 | Novel benzylamine derivatives as CETP inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-08-10 | — | — | US | disclosed |
| WO-2006073973-A2 | NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | REDDY US THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | PSMG3, HSPA5, TTR | SMN1; SMN2 21/4885MEN1 2173/4885KMT2A 3934/4885 |
| US-20070299068-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | SMN1; SMN2 3609/4885MEN1 4800/4885KMT2A 4464/4885 |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | SMN1; SMN2 2443/4885MEN1 2977/4885KMT2A 3057/4885 |
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | SMN1; SMN2 1776/4885MEN1 782/4885KMT2A 2892/4885 |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | CETP, NPC1, DBI | SMN1; SMN2 3792/4885MEN1 2159/4885KMT2A 1742/4885 |
| US-20060178514-A1 | Novel benzylamine derivatives as CETP inhibitors | CETP, NPC1, LIPC | SMN1; SMN2 3687/4885MEN1 3197/4885KMT2A 855/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | SMN1; SMN2 3169/4885MEN1 1615/4885KMT2A 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.